Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar

• Published in: Malaria journal Vol. 17; no. 1; pp. 126 - 10
• Main Authors: Lohy Das, Jesmin Permala, Kyaw, Myat P, Nyunt, Myat H, Chit, Khin, Aye, Kyin H, Aye, Moe M, Karlsson, Mats O, Bergstrand, Martin, Tarning, Joel
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 23.03.2018; BioMed Central; BMC
• Subjects: Antimalarials - pharmacokinetics; Antimalarials - pharmacology; Antimalarials - therapeutic use; Artemisinin; Artemisinins - pharmacology; Artesunate - pharmacokinetics; Artesunate - therapeutic use; Drug Resistance; Drug therapy; Health aspects; Humans; Malaria; Malaria, Falciparum - drug therapy; Malaria, Falciparum - epidemiology; Malaria, Falciparum - parasitology; Myanmar - epidemiology; Parasite clearance; Pharmacodynamics; Pharmacokinetics; Plasmodium falciparum; Plasmodium falciparum - drug effects; Resistance; Statistical models; Myanmar; Resistance; Pharmacodynamics; Nonlinear mixed-effects modelling; Malaria; Artemisinin; Parasite clearance; Pharmacokinetics
• ISSN: 1475-2875; 1475-2875
• DOI: 10.1186/s12936-018-2278-5

Artemisinins are the most effective anti-malarial drugs for uncomplicated and severe Plasmodium falciparum malaria. However, widespread artemisinin resistance in the Greater Mekong Region of Southeast Asia is threatening the possibility to control and eliminate malaria. This work aimed to evaluate the pharmacokinetic and pharmacodynamic properties of artesunate and its active metabolite, dihydroartemisinin, in patients with sensitive and resistant falciparum infections in Southern Myanmar. In addition, a simple nomogram previously developed to identify artemisinin resistant malaria infections was evaluated. Fifty-three (n = 53) patients were recruited and received daily oral artesunate monotherapy (4 mg/kg) for 7 days. Frequent artesunate and dihydroartemisinin plasma concentration measurements and parasite microscopy counts were obtained and evaluated using nonlinear mixed-effects modelling. The absorption of artesunate was best characterized by a transit-compartment (n = 3) model, followed by one-compartment disposition models for artesunate and dihydroartemisinin. The drug-dependent parasite killing effect of dihydroartemisinin was described using an Emax function, with a mixture model discriminating between artemisinin sensitive and resistant parasites. Overall, 56% of the studied population was predicted to have resistant malaria infections. Application of the proposed nomogram to identify artemisinin-resistant malaria infections demonstrated an overall sensitivity of 90% compared to 55% with the traditional day-3 positivity test. The pharmacokinetic-pharmacodynamic properties of artesunate and dihydroartemisinin were well-characterized with a mixture model to differentiate between drug sensitive and resistant infections in these patients. More than half of all patients recruited in this study had artemisinin-resistant infections. The relatively high sensitivity of the proposed nomogram highlights its potential clinical usefulness.